Latest News and Press Releases

Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen...

WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial...

WALTHAM, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from six abstracts will be presented at the...

WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be...

WALTHAM, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....

All evaluable patients experienced tumor shrinkageProtocol defined response criteria achieved and trial expansion ongoing WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:...

WALTHAM, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor...

ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of...

WALTHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce second-quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.S. financial...

WALTHAM, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce a new partnership supporting the Pan-Mass Challenge...